SEM3A_HUMAN
ID SEM3A_HUMAN Reviewed; 771 AA.
AC Q14563;
DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT 01-NOV-1996, sequence version 1.
DT 03-AUG-2022, entry version 194.
DE RecName: Full=Semaphorin-3A;
DE AltName: Full=Semaphorin III;
DE Short=Sema III;
DE Flags: Precursor;
GN Name=SEMA3A; Synonyms=SEMAD;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA].
RC TISSUE=Fetal brain;
RX PubMed=8269517; DOI=10.1016/0092-8674(93)90625-z;
RA Kolodkin A.L., Matthes D.J., Goodman C.S.;
RT "The semaphorin genes encode a family of transmembrane and secreted growth
RT cone guidance molecules.";
RL Cell 75:1389-1399(1993).
RN [2]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=12853948; DOI=10.1038/nature01782;
RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA Wilson R.K.;
RT "The DNA sequence of human chromosome 7.";
RL Nature 424:157-164(2003).
RN [3]
RP INVOLVEMENT IN HH16, AND FUNCTION.
RX PubMed=22416012; DOI=10.1093/humrep/des022;
RA Young J., Metay C., Bouligand J., Tou B., Francou B., Maione L., Tosca L.,
RA Sarfati J., Brioude F., Esteva B., Briand-Suleau A., Brisset S.,
RA Goossens M., Tachdjian G., Guiochon-Mantel A.;
RT "SEMA3A deletion in a family with Kallmann syndrome validates the role of
RT semaphorin 3A in human puberty and olfactory system development.";
RL Hum. Reprod. 27:1460-1465(2012).
RN [4]
RP TISSUE SPECIFICITY.
RX PubMed=28270793; DOI=10.3389/fneur.2017.00049;
RA Lindholm T., Risling M., Carlstedt T., Hammarberg H., Wallquist W.,
RA Cullheim S., Skoeld M.K.;
RT "Expression of Semaphorins, Neuropilins, VEGF, and Tenascins in Rat and
RT Human Primary Sensory Neurons after a Dorsal Root Injury.";
RL Front. Neurol. 8:49-49(2017).
RN [5]
RP VARIANT [LARGE SCALE ANALYSIS] THR-131.
RX PubMed=16959974; DOI=10.1126/science.1133427;
RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA Velculescu V.E.;
RT "The consensus coding sequences of human breast and colorectal cancers.";
RL Science 314:268-274(2006).
RN [6]
RP VARIANT SER-396.
RX PubMed=21248752; DOI=10.1038/nature09639;
RA Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., Davies H.,
RA Jones D., Lin M.L., Teague J., Bignell G., Butler A., Cho J.,
RA Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C., Jia M.,
RA Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A., Mudie L.,
RA Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S., Kahnoski R.J.,
RA Anema J., Tuveson D.A., Perez-Mancera P.A., Mustonen V., Fischer A.,
RA Adams D.J., Rust A., Chan-On W., Subimerb C., Dykema K., Furge K.,
RA Campbell P.J., Teh B.T., Stratton M.R., Futreal P.A.;
RT "Exome sequencing identifies frequent mutation of the SWI/SNF complex gene
RT PBRM1 in renal carcinoma.";
RL Nature 469:539-542(2011).
RN [7]
RP VARIANTS HH16 TRP-66; SER-153; VAL-400; ILE-435; ALA-688; GLN-730 AND
RP HIS-733, AND CHARACTERIZATION OF VARIANTS HH16 TRP-66; SER-153; VAL-400;
RP ILE-435; ALA-688; GLN-730 AND HIS-733.
RX PubMed=22927827; DOI=10.1371/journal.pgen.1002896;
RA Hanchate N.K., Giacobini P., Lhuillier P., Parkash J., Espy C.,
RA Fouveaut C., Leroy C., Baron S., Campagne C., Vanacker C., Collier F.,
RA Cruaud C., Meyer V., Garcia-Pinero A., Dewailly D., Cortet-Rudelli C.,
RA Gersak K., Metz C., Chabrier G., Pugeat M., Young J., Hardelin J.P.,
RA Prevot V., Dode C.;
RT "SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with
RT Kallmann syndrome.";
RL PLoS Genet. 8:E1002896-E1002896(2012).
RN [8]
RP VARIANTS HH16 TRP-66; ARG-82; SER-153; THR-342; ILE-435; GLY-447; TRP-484;
RP MET-657 AND GLN-730.
RX PubMed=25077900; DOI=10.1210/jc.2014-2110;
RA Marcos S., Sarfati J., Leroy C., Fouveaut C., Parent P., Metz C.,
RA Wolczynski S., Gerard M., Bieth E., Kurtz F., Verier-Mine O., Perrin L.,
RA Archambeaud F., Cabrol S., Rodien P., Hove H., Prescott T., Lacombe D.,
RA Christin-Maitre S., Touraine P., Hieronimus S., Dewailly D., Young J.,
RA Pugeat M., Hardelin J.P., Dode C.;
RT "The prevalence of CHD7 missense versus truncating mutations is higher in
RT patients with Kallmann syndrome than in typical CHARGE patients.";
RL J. Clin. Endocrinol. Metab. 99:E2138-2143(2014).
CC -!- FUNCTION: Involved in the development of the olfactory system and in
CC neuronal control of puberty. Induces the collapse and paralysis of
CC neuronal growth cones. Could serve as a ligand that guides specific
CC growth cones by a motility-inhibiting mechanism. Binds to the complex
CC neuropilin-1/plexin-1. {ECO:0000269|PubMed:22416012}.
CC -!- SUBUNIT: Interacts with PLXND1. {ECO:0000250}.
CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000250}.
CC -!- TISSUE SPECIFICITY: Expressed in the dorsal root ganglia.
CC {ECO:0000269|PubMed:28270793}.
CC -!- DOMAIN: Strong binding to neuropilin is mediated by the carboxy third
CC of the protein.
CC -!- DISEASE: Hypogonadotropic hypogonadism 16 with or without anosmia
CC (HH16) [MIM:614897]: A disorder characterized by absent or incomplete
CC sexual maturation by the age of 18 years, in conjunction with low
CC levels of circulating gonadotropins and testosterone and no other
CC abnormalities of the hypothalamic-pituitary axis. In some cases, it is
CC associated with non-reproductive phenotypes, such as anosmia, cleft
CC palate, and sensorineural hearing loss. Anosmia or hyposmia is related
CC to the absence or hypoplasia of the olfactory bulbs and tracts.
CC Hypogonadism is due to deficiency in gonadotropin-releasing hormone and
CC probably results from a failure of embryonic migration of gonadotropin-
CC releasing hormone-synthesizing neurons. In the presence of anosmia,
CC idiopathic hypogonadotropic hypogonadism is referred to as Kallmann
CC syndrome, whereas in the presence of a normal sense of smell, it has
CC been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).
CC {ECO:0000269|PubMed:22416012, ECO:0000269|PubMed:22927827,
CC ECO:0000269|PubMed:25077900}. Note=The disease may be caused by
CC variants affecting distinct genetic loci, including the gene
CC represented in this entry.
CC -!- SIMILARITY: Belongs to the semaphorin family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; L26081; AAA65938.1; -; mRNA.
DR EMBL; AC004451; AAS00353.1; -; Genomic_DNA.
DR EMBL; AC004848; AAC78622.1; -; Genomic_DNA.
DR CCDS; CCDS5599.1; -.
DR PIR; D49423; D49423.
DR RefSeq; NP_006071.1; NM_006080.2.
DR RefSeq; XP_005250167.1; XM_005250110.3.
DR RefSeq; XP_005250168.1; XM_005250111.4.
DR RefSeq; XP_006715902.1; XM_006715839.3.
DR RefSeq; XP_011514036.1; XM_011515734.2.
DR RefSeq; XP_016867162.1; XM_017011673.1.
DR AlphaFoldDB; Q14563; -.
DR SMR; Q14563; -.
DR BioGRID; 115650; 12.
DR CORUM; Q14563; -.
DR DIP; DIP-5744N; -.
DR IntAct; Q14563; 1.
DR MINT; Q14563; -.
DR STRING; 9606.ENSP00000265362; -.
DR GlyGen; Q14563; 4 sites, 2 O-linked glycans (1 site).
DR iPTMnet; Q14563; -.
DR PhosphoSitePlus; Q14563; -.
DR BioMuta; SEMA3A; -.
DR DMDM; 8134674; -.
DR EPD; Q14563; -.
DR jPOST; Q14563; -.
DR MassIVE; Q14563; -.
DR MaxQB; Q14563; -.
DR PaxDb; Q14563; -.
DR PeptideAtlas; Q14563; -.
DR PRIDE; Q14563; -.
DR ProteomicsDB; 60045; -.
DR Antibodypedia; 29608; 325 antibodies from 32 providers.
DR DNASU; 10371; -.
DR Ensembl; ENST00000265362.9; ENSP00000265362.3; ENSG00000075213.11.
DR Ensembl; ENST00000436949.5; ENSP00000415260.1; ENSG00000075213.11.
DR GeneID; 10371; -.
DR KEGG; hsa:10371; -.
DR MANE-Select; ENST00000265362.9; ENSP00000265362.3; NM_006080.3; NP_006071.1.
DR UCSC; uc003uhz.4; human.
DR CTD; 10371; -.
DR DisGeNET; 10371; -.
DR GeneCards; SEMA3A; -.
DR GeneReviews; SEMA3A; -.
DR HGNC; HGNC:10723; SEMA3A.
DR HPA; ENSG00000075213; Tissue enhanced (retina).
DR MalaCards; SEMA3A; -.
DR MIM; 603961; gene.
DR MIM; 614897; phenotype.
DR neXtProt; NX_Q14563; -.
DR OpenTargets; ENSG00000075213; -.
DR Orphanet; 130; Brugada syndrome.
DR Orphanet; 478; Kallmann syndrome.
DR PharmGKB; PA35645; -.
DR VEuPathDB; HostDB:ENSG00000075213; -.
DR eggNOG; KOG3611; Eukaryota.
DR GeneTree; ENSGT00940000158203; -.
DR HOGENOM; CLU_009051_5_0_1; -.
DR InParanoid; Q14563; -.
DR OMA; GDYENTW; -.
DR OrthoDB; 297290at2759; -.
DR PhylomeDB; Q14563; -.
DR TreeFam; TF316102; -.
DR PathwayCommons; Q14563; -.
DR Reactome; R-HSA-399954; Sema3A PAK dependent Axon repulsion.
DR Reactome; R-HSA-399955; SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion.
DR Reactome; R-HSA-399956; CRMPs in Sema3A signaling.
DR SignaLink; Q14563; -.
DR SIGNOR; Q14563; -.
DR BioGRID-ORCS; 10371; 10 hits in 1076 CRISPR screens.
DR ChiTaRS; SEMA3A; human.
DR GeneWiki; SEMA3A; -.
DR GenomeRNAi; 10371; -.
DR Pharos; Q14563; Tbio.
DR PRO; PR:Q14563; -.
DR Proteomes; UP000005640; Chromosome 7.
DR RNAct; Q14563; protein.
DR Bgee; ENSG00000075213; Expressed in stromal cell of endometrium and 128 other tissues.
DR ExpressionAtlas; Q14563; baseline and differential.
DR Genevisible; Q14563; HS.
DR GO; GO:0030424; C:axon; IBA:GO_Central.
DR GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR GO; GO:0045499; F:chemorepellent activity; IBA:GO_Central.
DR GO; GO:0038191; F:neuropilin binding; ISS:BHF-UCL.
DR GO; GO:0030215; F:semaphorin receptor binding; IBA:GO_Central.
DR GO; GO:0006915; P:apoptotic process; IEA:Ensembl.
DR GO; GO:0048846; P:axon extension involved in axon guidance; ISS:BHF-UCL.
DR GO; GO:0007411; P:axon guidance; IBA:GO_Central.
DR GO; GO:0060385; P:axonogenesis involved in innervation; ISS:BHF-UCL.
DR GO; GO:0150020; P:basal dendrite arborization; ISS:ARUK-UCL.
DR GO; GO:0008045; P:motor neuron axon guidance; IBA:GO_Central.
DR GO; GO:0050919; P:negative chemotaxis; IBA:GO_Central.
DR GO; GO:0048843; P:negative regulation of axon extension involved in axon guidance; IBA:GO_Central.
DR GO; GO:0010977; P:negative regulation of neuron projection development; IMP:ParkinsonsUK-UCL.
DR GO; GO:0021675; P:nerve development; ISS:BHF-UCL.
DR GO; GO:0001755; P:neural crest cell migration; IBA:GO_Central.
DR GO; GO:1901166; P:neural crest cell migration involved in autonomic nervous system development; ISS:BHF-UCL.
DR GO; GO:0001764; P:neuron migration; ISS:BHF-UCL.
DR GO; GO:0021772; P:olfactory bulb development; IMP:UniProtKB.
DR GO; GO:0030335; P:positive regulation of cell migration; IBA:GO_Central.
DR GO; GO:0046330; P:positive regulation of JNK cascade; TAS:ARUK-UCL.
DR GO; GO:2001224; P:positive regulation of neuron migration; IBA:GO_Central.
DR GO; GO:0048841; P:regulation of axon extension involved in axon guidance; IDA:UniProtKB.
DR GO; GO:0071526; P:semaphorin-plexin signaling pathway; IBA:GO_Central.
DR GO; GO:1902285; P:semaphorin-plexin signaling pathway involved in neuron projection guidance; ISS:BHF-UCL.
DR GO; GO:0048880; P:sensory system development; TAS:BHF-UCL.
DR GO; GO:0061549; P:sympathetic ganglion development; ISS:BHF-UCL.
DR GO; GO:0048485; P:sympathetic nervous system development; TAS:BHF-UCL.
DR GO; GO:0097490; P:sympathetic neuron projection extension; ISS:BHF-UCL.
DR GO; GO:0097491; P:sympathetic neuron projection guidance; ISS:BHF-UCL.
DR CDD; cd11249; Sema_3A; 1.
DR Gene3D; 2.130.10.10; -; 1.
DR Gene3D; 2.60.40.10; -; 1.
DR InterPro; IPR007110; Ig-like_dom.
DR InterPro; IPR036179; Ig-like_dom_sf.
DR InterPro; IPR013783; Ig-like_fold.
DR InterPro; IPR003599; Ig_sub.
DR InterPro; IPR041416; IL-1RAcP-like_ig.
DR InterPro; IPR016201; PSI.
DR InterPro; IPR042820; Sema3A_sema.
DR InterPro; IPR001627; Semap_dom.
DR InterPro; IPR036352; Semap_dom_sf.
DR InterPro; IPR027231; Semaphorin.
DR InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf.
DR PANTHER; PTHR11036; PTHR11036; 1.
DR Pfam; PF18452; Ig_6; 1.
DR Pfam; PF01403; Sema; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00423; PSI; 1.
DR SMART; SM00630; Sema; 1.
DR SUPFAM; SSF101912; SSF101912; 1.
DR SUPFAM; SSF48726; SSF48726; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
DR PROSITE; PS51004; SEMA; 1.
PE 1: Evidence at protein level;
KW Developmental protein; Differentiation; Disease variant; Disulfide bond;
KW Glycoprotein; Hypogonadotropic hypogonadism; Immunoglobulin domain;
KW Kallmann syndrome; Neurogenesis; Reference proteome; Secreted; Signal.
FT SIGNAL 1..20
FT /evidence="ECO:0000255"
FT CHAIN 21..771
FT /note="Semaphorin-3A"
FT /id="PRO_0000032303"
FT DOMAIN 31..514
FT /note="Sema"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00352"
FT DOMAIN 580..664
FT /note="Ig-like C2-type"
FT REGION 728..771
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 748..771
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT CARBOHYD 53
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 125
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 590
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT DISULFID 103..114
FT /evidence="ECO:0000250"
FT DISULFID 132..141
FT /evidence="ECO:0000250"
FT DISULFID 269..381
FT /evidence="ECO:0000250"
FT DISULFID 293..341
FT /evidence="ECO:0000250"
FT DISULFID 517..535
FT /evidence="ECO:0000250"
FT DISULFID 649..722
FT /evidence="ECO:0000250"
FT VARIANT 66
FT /note="R -> W (in HH16; phenotype consistent with Kallmann
FT syndrome; dbSNP:rs199979628)"
FT /evidence="ECO:0000269|PubMed:22927827,
FT ECO:0000269|PubMed:25077900"
FT /id="VAR_069200"
FT VARIANT 82
FT /note="L -> R (in HH16; unknown pathological significance)"
FT /evidence="ECO:0000269|PubMed:25077900"
FT /id="VAR_072986"
FT VARIANT 131
FT /note="A -> T (in a breast cancer sample; somatic mutation;
FT dbSNP:rs143007146)"
FT /evidence="ECO:0000269|PubMed:16959974"
FT /id="VAR_036283"
FT VARIANT 153
FT /note="N -> S (in HH16; phenotype consistent with Kallmann
FT syndrome; dbSNP:rs139295139)"
FT /evidence="ECO:0000269|PubMed:22927827,
FT ECO:0000269|PubMed:25077900"
FT /id="VAR_069201"
FT VARIANT 342
FT /note="M -> T (in HH16; phenotype consistent with Kallmann
FT syndrome)"
FT /evidence="ECO:0000269|PubMed:25077900"
FT /id="VAR_072987"
FT VARIANT 396
FT /note="P -> S (found in a renal cell carcinoma sample;
FT somatic mutation; dbSNP:rs866354226)"
FT /evidence="ECO:0000269|PubMed:21248752"
FT /id="VAR_064749"
FT VARIANT 400
FT /note="I -> V (in HH16; phenotype consistent with Kallmann
FT syndrome; digenic; found in a patient also carrying
FT mutation Cys-268 in PROKR2; dbSNP:rs36026860)"
FT /evidence="ECO:0000269|PubMed:22927827"
FT /id="VAR_069202"
FT VARIANT 435
FT /note="V -> I (in HH16; phenotype consistent with Kallmann
FT syndrome; digenic; found in patients also carrying mutation
FT Cys-268 in PROKR2 or mutation Arg-687 in FGFR1;
FT dbSNP:rs147436181)"
FT /evidence="ECO:0000269|PubMed:22927827,
FT ECO:0000269|PubMed:25077900"
FT /id="VAR_069203"
FT VARIANT 447
FT /note="D -> G (in HH16; phenotype consistent with Kallmann
FT syndrome; dbSNP:rs761486957)"
FT /evidence="ECO:0000269|PubMed:25077900"
FT /id="VAR_072988"
FT VARIANT 484
FT /note="R -> W (in HH16; unknown pathological significance;
FT dbSNP:rs137871935)"
FT /evidence="ECO:0000269|PubMed:25077900"
FT /id="VAR_072989"
FT VARIANT 657
FT /note="I -> M (in HH16; phenotype consistent with Kallmann
FT syndrome; dbSNP:rs748219597)"
FT /evidence="ECO:0000269|PubMed:25077900"
FT /id="VAR_072990"
FT VARIANT 688
FT /note="T -> A (in HH16; phenotype consistent with Kallmann
FT syndrome; digenic; found in a patient also carrying
FT mutation Asp-217 in KAL1; dbSNP:rs318240751)"
FT /evidence="ECO:0000269|PubMed:22927827"
FT /id="VAR_069204"
FT VARIANT 730
FT /note="R -> Q (in HH16; phenotype consistent with Kallmann
FT syndrome; dbSNP:rs318240752)"
FT /evidence="ECO:0000269|PubMed:22927827,
FT ECO:0000269|PubMed:25077900"
FT /id="VAR_069205"
FT VARIANT 733
FT /note="R -> H (in HH16; phenotype consistent with Kallmann
FT syndrome; dbSNP:rs318240753)"
FT /evidence="ECO:0000269|PubMed:22927827"
FT /id="VAR_069206"
SQ SEQUENCE 771 AA; 88889 MW; 9985F8D3EAED8456 CRC64;
MGWLTRIVCL FWGVLLTARA NYQNGKNNVP RLKLSYKEML ESNNVITFNG LANSSSYHTF
LLDEERSRLY VGAKDHIFSF DLVNIKDFQK IVWPVSYTRR DECKWAGKDI LKECANFIKV
LKAYNQTHLY ACGTGAFHPI CTYIEIGHHP EDNIFKLENS HFENGRGKSP YDPKLLTASL
LIDGELYSGT AADFMGRDFA IFRTLGHHHP IRTEQHDSRW LNDPKFISAH LISESDNPED
DKVYFFFREN AIDGEHSGKA THARIGQICK NDFGGHRSLV NKWTTFLKAR LICSVPGPNG
IDTHFDELQD VFLMNFKDPK NPVVYGVFTT SSNIFKGSAV CMYSMSDVRR VFLGPYAHRD
GPNYQWVPYQ GRVPYPRPGT CPSKTFGGFD STKDLPDDVI TFARSHPAMY NPVFPMNNRP
IVIKTDVNYQ FTQIVVDRVD AEDGQYDVMF IGTDVGTVLK VVSIPKETWY DLEEVLLEEM
TVFREPTAIS AMELSTKQQQ LYIGSTAGVA QLPLHRCDIY GKACAECCLA RDPYCAWDGS
ACSRYFPTAK RRTRRQDIRN GDPLTHCSDL HHDNHHGHSP EERIIYGVEN SSTFLECSPK
SQRALVYWQF QRRNEERKEE IRVDDHIIRT DQGLLLRSLQ QKDSGNYLCH AVEHGFIQTL
LKVTLEVIDT EHLEELLHKD DDGDGSKTKE MSNSMTPSQK VWYRDFMQLI NHPNLNTMDE
FCEQVWKRDR KQRRQRPGHT PGNSNKWKHL QENKKGRNRR THEFERAPRS V
